Meta-analyses | |||
---|---|---|---|
N (%) | OR (95% CI) | p Value | |
DRB1*04 | |||
aβ2GP1 IgG | 67 (46.5) | 2.66 (1.81 to 3.91) | <0.00001 |
aCL IgG | 60 (41.4) | 1.99 (1.35 to 2.93) | 0.0005 |
aCL IgM | 59 (39.1) | 1.76 (1.20 to 2.58) | 0.004 |
aPT IgG† | 32 (40.0) | 1.69 (1.04 to 2.76) | 0.03 |
≥2aPL‡ | 63 (44.4) | 2.33 (1.58 to 3.44) | <0.00001 |
LAC§ | 40 (47.1) | 2.57 (1.53 to 4.32) | 0.0003 |
DRB1*13 | |||
aβ2GP1 IgG | 48 (33.3) | 1.69 (1.13 to 2.52) | 0.01 |
aCL IgG | 47 (32.4) | 1.60 (1.07 to 2.40) | 0.02 |
aCL IgM | 43 (28.5) | 1.25 (0.83 to 1.88) | 0.28 |
aPT IgG† | 28 (35.0) | 1.66 (1.01 to 2.75) | 0.05 |
≥2aPL‡ | 45 (31.7) | 1.51 (1.00 to 2.28) | 0.05 |
LAC§ | 28 (32.9) | 1.65 (0.96 to 2.86) | 0.06 |
N represents number of cases positive for the particular DRB1 allele and positive for the particular antibody test; (%) represents percentage of the total number positive for the antibody test (eg, for the first line, 46.5), how many patients out of all who have had aβ2GP1 IgG antibodies are DRB1*04 positive).
†N=593.
‡N=661.
§Only analysed in the Stockholm group, N=363.
a, anti; ≥2aPL, at least two positive tests of aβ2GP-1, aCL IgG and aCL IgM; β2GP1, β2-glycoprotein 1; CL, cardolipin; Ig, immunoglobulin; LAC, lupus anticoagulant; PT, prothrombin.